| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Service de Pneumologie et Réanimation, Hôpital de l'Hôtel Dieu, Université de Pierre et Marie Curie, Paris, France. 2 Association des Pneumologues d'Ile-de-France, Sucy-en-Brie, France
CORRESPONDENCE: N. Roche, Service de Pneumologie et Réanimation, Hôpital de l'Hôtel-Dieu, 1, place du Parvis Notre-Dame, F-75004, Paris, France. Fax: 33 142348448
Keywords: ß2-agonists, bronchodilators, chronic obstructive pulmonary disease, corticosteroids, guidelines, treatment
Received: February 9, 2001
Accepted August 3, 2001
This study was supported by Boehringer Ingelheim France.
The main purpose of this study was to assess whether pharmacological treatments prescribed by respiratory physicians to patients with chronic obstructive pulmonary disease (COPD) were consistent with the guidelines.
The treatments prescribed by respiratory physicians to 631 consecutive patients with COPD, compared to 879 asthmatics were prospectively recorded. All subjects underwent peak expiratory flow rate measurement, spirometry and assessment of recent evolution and dyspnoea (visual analogue and Medical Research Council scales). Patients with COPD received more treatments than asthmatics (mean±sd: 2.6±0.5 versus 2.2±0.4, p<0.0001). Treatments administered to patients with COPD were ß2-agonists in 78% (versus 94% in asthmatics), anticholinergic agents (AC) in 56% (versus 16% in asthma), methylxanthines in 31% (versus 15% in asthma) and inhaled corticosteroids in 76% (versus 85% in asthma). Intensity of treatment was influenced by disease severity for all treatments except AC.
In conclusion, pharmacological treatment of chronic obstructive pulmonary disease by respiratory physicians is only partially consistent with current guidelines, with a high proportion of inhaled corticosteroid prescriptions and a relative under-use of anticholinergic agents; this most likely reflects the persistent uncertainties of physicians, and emphasizes that more efforts are required to improve implementation of chronic obstructive pulmonary disease guidelines and assess the efficacy and cost-effectiveness of recommended strategies.
This article has been cited by other articles:
|
|
 |
|
  N. Roche Where current pharmacological therapies fall short in COPD: symptom control is not enough Eur. Respir. Rev., September 1, 2007; 16(105): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Talamo, M. M. de Oca, R. Halbert, R. Perez-Padilla, J. R. B. Jardim, A. Muino, M. V. Lopez, G. Valdivia, J. Pertuze, D. Moreno, et al. Diagnostic Labeling of COPD in Five Latin American Cities Chest, January 1, 2007; 131(1): 60 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dusser, M-L. Bravo, P. Iacono, and on behalf the MISTRAL study group The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J., March 1, 2006; 27(3): 547 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Lee and K. B. Weiss Fracture Risk Associated with Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., April 1, 2004; 169(7): 855 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Miravitlles Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease Eur. Respir. J., July 1, 2002; 20(1): 243 - 244. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
